Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Obama Signs 21st Century Cures Act Into Law



The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

Share this!

December 15, 2016 | by Sarah Hand, M.Sc.

This week, President Barack Obama signed the 21st Century Cures Act – a bill that promises additional funding for cancer research and opioid addiction prevention – into law. The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

In all, the 21st Century Cures Act will provide $6.3 billion in additional funding towards multiple large-scale projects. Under the bill, states will be provided with $1 billion in funding over a two year period to use towards the prevention and treatment of opioids and other drug addictions.

The bill will also change the way the US Food and Drug Administration (FDA) approves new drugs, potentially allowing them to accept alternative data sources to expedite the approvals process. Patient advocacy groups like Public Citizen have been strongly opposed to this part of the act, arguing that it will weaken the drug approvals process.

“This bill remains a bad deal for patient safety, offering a small, temporary and non-guaranteed increase in public research funding at the expense of permanently weakening oversight by the Food and Drug Administration,” said a spokesperson from Public Citizen. The group is a non-profit organization that aims to represent all US citizens, and their interests, in Washington, D.C.

The signing event represented a rare moment of bipartisanship, with both parties offering their support for the bill. “I hope this bodes well for what will come next year - that we're back working together,” said Biden.

The 21st Century Cures Act was passed in the US House of Representatives earlier this month in a landslide 392 to 26 vote. As predicted, the bill easily passed through the Senate to allow it to be signed into law before the close of 2016.

Keywords: Cancer, FDA, Opioids


Share this with your colleagues!

Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News

Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News

Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


One Patient’s Perspective on Clinical Trials


Planning and Conducting Trials of the Latest Immunotherapies

ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation

Medical Devices: Reviewing Regulatory Changes in the US and EU

Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.